273 related articles for article (PubMed ID: 35769225)
21. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
[TBL] [Abstract][Full Text] [Related]
23. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
24. Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region.
Resta E; Scioscia G; Lacedonia D; Quarato CMI; Panza F; Resta O; Lepore G; Buonamico E; Di Lecce V; Carpagnano GE; Barbaro MPF; Rossi N
BMC Health Serv Res; 2022 Oct; 22(1):1283. PubMed ID: 36284319
[TBL] [Abstract][Full Text] [Related]
25. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
[No Abstract] [Full Text] [Related]
26. A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD.
Cazzola M; Rogliani P; Calzetta L; Ora J; Matera MG
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):269-283. PubMed ID: 35475762
[TBL] [Abstract][Full Text] [Related]
27. DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.
Singh D; Litewka D; Páramo R; Rendon A; Sayiner A; Tanni SE; Acharya S; Aggarwal B; Ismaila AS; Sharma R; Daley-Yates P
Adv Ther; 2023 Oct; 40(10):4282-4297. PubMed ID: 37382864
[TBL] [Abstract][Full Text] [Related]
28. Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management.
Busse WW; Abbott CB; Germain G; Laliberté F; MacKnight SD; Jung Y; Duh MS; Averell CM
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2904-2913.e6. PubMed ID: 35752431
[TBL] [Abstract][Full Text] [Related]
29. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
[TBL] [Abstract][Full Text] [Related]
30. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
[TBL] [Abstract][Full Text] [Related]
31. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
[TBL] [Abstract][Full Text] [Related]
32. A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand.
Xu X; Milea D; Navarro Rojas AA; Braganza A; Holbrook T; Marett B; Young R; Scott RJ; Gribben B
Int J Chron Obstruct Pulmon Dis; 2021; 16():1835-1850. PubMed ID: 34177262
[TBL] [Abstract][Full Text] [Related]
33. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
35. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
Panettieri RA; Camargo CA; Cheema T; El Bayadi SG; Fiel S; Vila TM; Jain RG; Midwinter D; Thomashow B; Ludwig-Sengpiel A; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2022; 17():2043-2052. PubMed ID: 36072608
[TBL] [Abstract][Full Text] [Related]
36. Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations.
Usmani OS; Scichilone N; Mignot B; Belmans D; Van Holsbeke C; De Backer J; De Maria R; Cuoghi E; Topole E; Georges G
Int J Chron Obstruct Pulmon Dis; 2020; 15():2433-2440. PubMed ID: 33116458
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
Halpin DMG; Kendall R; Shukla S; Martin A; Shah D; Midwinter D; Beeh KM; Kocks JWH; Jones PW; Compton C; Risebrough NA; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2022; 17():2745-2755. PubMed ID: 36317185
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
Requena G; Czira A; Banks V; Wood R; Tritton T; Castillo C; Yeap J; Wild R; Compton C; Rothnie KJ; Herth FJF; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():2039-2054. PubMed ID: 37731774
[TBL] [Abstract][Full Text] [Related]
39. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
[TBL] [Abstract][Full Text] [Related]
40. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
